Principles for Data Access & Utilization in Medical and Digital Health Technologies

Medtech meets AI: Join Morrison Foerster to explore the evolving legal landscape surrounding artificial intelligence in medical devices.

WASHINGTON, D.C.—AdvaMed, the Medtech Association, is among 67 stakeholder groups, including patient advocacy groups and state medtech and life sciences associations, urging the Centers for Medicare and Medicaid Services (CMS) to create a timely, streamlined pathway for Medicare patients to access FDA-authorized breakthrough medical technology. 

WASHINGTON, D.C.—AdvaMed, the medtech association, today welcomed the kickoff of the latest Medical Device User Fee Amendments (MDUFA) discussion at a public meeting at FDA headquarters. Three AdvaMed senior staff members encouraged the agency to build on the successes of the prior five such agreements to ensure the next agreement, MDUFA VI, delivers strong results for the American public.

AdvaMed, the medtech association, released the following statement today from Shaye Mandle, executive director of the organization’s Digital Health Tech division, on the announcement from the White House, CMS, and HHS of a voluntary pledge by health care entities to make patient data more accessible and delivered faster between patients and providers.

WASHINGTON, D.C. – In a new op-ed in The Washington Times, Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, laid out medtech’s vital role in the Trump administration’s “Make America Healthy Again” initiative, calling for policies that ensure faster, broader access to lifesaving medtech.

WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the medtech association, issued the following statement on the White House’s “America’s AI Action Plan”:

Join Alexander Group to explore how you can refine your go-to-market strategies, optimize resource allocation and strengthen provider engagement in a constrained and competitive environment.

Join cyber experts for the Cybersecurity Summit that will address the latest industry issues and changes related to FDA requirements.